Locations

New York, NY, USA · Canal Street, New York, NY, USA

industry

Biotechnology

Size

51 - 200 employees

Stage

Series B

founded in

2019

Comprehensively mapping and reprogramming the immune system with single-cell biology and AI to power new therapeutic discoveries, accelerate drug development, and improve patient outcomes.


Is this your company?

If you're responsible for hiring at this company, make sure your company and job information are always up to date to attract top talent from the Israel VC Forum network.

Something looks off?
Open jobs at Immunai

On-site & Remote